Canaccord Genuity Annual Growth Conference 2013- Webcast Presentation Transcripts

Date: August 14 - 15, 2013

 Canaccord Genuity hosted its 30th Annual Growth Conference, a premier investment forum for innovative small and mid-cap growth companies from the US, Canada, and the UK. refinance home The Boston-based conference demonstrates Canaccord Genuity's focus on bringing institutional investors some of the most interesting and actionable ideas from a growing, global universe of small and mid-cap companies. 

Access Transcripts of Companies' webcast presentations here

Webush Life Sciences Conference 2013- Webcast Presentations Transcripts

Date: August 13 & 14 2013

Wedbush Securities, one of the nation’s leading broker-dealers and award-winning equity research firms, hosted its annual Wedbush PacGrow Life Sciences Management Access Conference in New York from August 13 - 14, 2013. The conference connects institutional investors with management teams and senior 
executives from more than 75 prominent public and private companies across sectors including 
biotechnology, medical devices, emerging pharmaceuticals, healthcare services, managed care, medical 
diagnostics and life sciences tools.conference calling

The following companies presented at the Wedbush Life Sciences Management Access Conference: Alexza, Algeta, Amicus Therapeutics, Anacor Pharmaceuticals, Ariosa Diagnostics, Avanir Pharmaceuticals, AxoGen, Biodel, Cadence Pharmaceuticals, Bluebird Bio, Cara Therapeutics, Cardica, Catabasis Pharmaceuticals, CellScape, Cepheid, Cerus, Chelsea Therapeutics, Civitas Therapeutics, CONMED Corporation, Coronado Biosciences, Curis, Delcath Systems, diaDexus, Durata Therapeutics, EndoStim, Emergent BioSolutions, Epizyme, Endocyte, Forma Therapeutics, Genocea, Gentium S.p.A., Good Start Genetics, GTx, Inc., Illumina, ImmunoGen, Insmed, Intercept Pharmaceuticals, IRIDEX, KellBenX, Kindred Bio, Lexicon Pharmaceuticals, Medivation, MEI Pharma, Metabolon, Natera, Novavax, NPS Pharmaceuticals, Ohr Pharmaceutical, Omeros Corp., OncoGenex Pharmaceuticals, Oncolytics Biotech, Oncothyreon, OvaScience, Pacira Pharmaceuticals, Palatin Technologies, Peregrine Pharmaceuticals, Prosensa, Prothena Corporation, PTC Therapeutics, Receptos, Regado Biosciences, Relypsa, Sangamo BioSciences, Sarepta Therapeutics, Sequenom, SIGA Technologies, Spectral Diagnostics, Spectrum Pharmaceuticals, Stemline Therapeutics, Summit PLC, Sunesis Pharmaceuticals, Synageva Biopharma, Tekmira Pharmaceuticals, Ultragenyx, Verastem, Xencor, Xoma and Zalicus.

Access Transcripts of these webcast presentations here

INO OneMedForumNY2013 Transcript - Inovio Pharmaceuticals Inc.

Event:  Jun 27, 2013 8:00 AM ET

CEO speaks about synthetic DNA vaccines. Said that they Expect to bring a large pharma partnership with some of their programs at the OneMedForumNY2013 Conference. Also more on the proprietary electroporation delivery system .

Read here

ATVI - Business Update Call Transcript- Activision Blizzard Inc

Excerpt from the call Transcript:

"Activision Blizzard is announcing a very exciting transaction that represents the tremendous opportunity for the company and its shareholders. Activision Blizzard will acquire approximately 429 million shares and certain tax attributes from Vivendi in exchange for $5.8 billion in cash, approximately $13.60 a share before taking into account benefit to the company of these tax attributes.
Separately in a simultaneous transaction, in investor group led by Brian, Kelly and me will acquire approximately a 172 million shares from Vivendi for $2.3 billion in cash or approximately 13.60 per share. Brian and I are personally investing a combined a $100 million to purchase company shares from Vivendi through our investor group. Activision Blizzard share repurchase from Vivendi reduced the outstanding share count to approximately 690 million shares. This will be meaningfully accretive to Activision Blizzard shareholders."

Read here

PRGO - Perrigo Company Acquisition of Elan Corporation- Transcript

29-Jul-2013 8:30 ET

Excerpt from the transcript :

"welcome everyone to Perrigo's conference call announcing our acquisition of Elan Corporation, which will create an industry leading global healthcare company.
I have the pleasure of introducing Perrigo's shareholders to Kelly Martin, Elan's Executive Director and CEO; and Nigel Clerkin Elan's Chief Financial Officer. Also joining us on the call today is Judy Brown, Perrigo's Chief Financial Officer.
First, this is a really great day for both Perrigo and Elan employees, patients, customers and shareholders this transaction was unanimously approved by the Board of Directors of both companies and we are excited by the opportunities created through the combination of two great companies."

http://www.earningsimpact.com/Transcript/82580/PRGO/Perrigo-Company---Perrigo-Company-To-Acquire-Elan-Corporation

On Demand Earnings Call & Conference Call Transcript

Analysts & Investors, now you can order your choice of event transcript. You can request for transcripts you want from the Earnings Calls events & Conference call events available on Earnings Impact. The purchase option allows you to order the PDF version of the transcript which would be directly sent to you via email. 

Some of the events available are:

Verastem, Inc. Verastem Research and Development Day Call

Quicksilver Resources Inc. 2013 GHS 100 Energy Conference Call

Dunkin Brands Group Inc Jefferies 2013 Global Consumer Conference Call

The Western Union Company 33rd Annual William Blair Growth Stock Conference Call

Republic Services, Inc. Deutsche Bank 2013 Global Industrials & Basic Materials Conference Call

B&G Foods Holdings Corp. 33rd Annual Piper Jaffray Consumer Conference Call

Novartis AG Goldman Sachs 34th Annual Global Healthcare Conference Call

Imax Corporation Gabelli & Company's 5th Annual Movie & Entertainment Conference Call

Browse the list here 

Singapore Exchange Limited- Q4 2013 Earnings Call Transcript

Ticker: s68 SGX Exchange

Excerpt from the transcript -
This is Singapore Exchange's second best result ever. Our fourth quarter was a very strong quarter. I think many of you have follow that and follow our continuous reporting of volumes and value traded. We recorded revenues of 202 million, up 28% since last year. And we had an operating profit of 121 million up nearly 40% from last year.
We had an underlying profit, underlying net profit of 103 million, up 40% from last year and a net profit to the impairment of our holdings into BUC of 88 million, so a very strong fourth quarter. And if you go back and look at the full year of FY'13, we have seen that the securities market finally in the second half got a little bit more active and we saw the volume and the value traded go up.

Transcript Published here